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Background. Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of
sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in pa-
tients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice.
Methods. Hepatitis C Virus Therapeutic Registry and Research Network is an international, prospective observational study eval-
uating patients treated in usual clinical practice. Patients with GT3 HCV were analyzed to assess predictors of treatment response and
adverse events using descriptive statistics and multivariable logistic regression.
Results. Treatment outcomes were available for 197 patients treated with SOF and ribavirin (RBV), with or without peginterferon,
including 54% with cirrhosis and 49% who failed prior therapy. Of 178 patients treated with SOF/RBV, 60% achieved SVR at 12 weeks
(SVR12), compared with 84% of 19 patients treated with SOF/peginterferon/RBV. For patients treated with SOF/RBV, the SVR12 rate
was 58% in treatment-naive patients with cirrhosis, and 42% in those with cirrhosis who failed prior therapy. In noncirrhotic patients,
SVR12 rates were 89% in treatment-naive and 88% in treatment-experienced patients. After controlling for age and sex, absence of cir-
rhosis (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.78–14.74), albumin levels ≥3.2 g/dL (OR, 12.48; 95% CI, 3.86–40.33), and
platelet count >105 cells/µL (OR, 7.44; 95% CI, 3.51–15.78) were associated with greater odds of SVR12.
Conclusions. SVR rates were acceptable in patients with GT3 HCV without cirrhosis; however, in those with cirrhosis, treatment
with SOF/RBV was suboptimal, highlighting the need for new therapies for this population.
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Chronic hepatitis C virus (HCV) infection continues to be a
major global public health problem, with recent estimates sug-
gesting that >103 million people are infected worldwide [1].
There is wide geographical variation in HCV genotype distribu-
tion; genotype 1 is most common (46%), followed by genotype 3
(GT3) (22%) [1]. Chronic infection leads to progressive liver
fibrosis that may eventually lead to cirrhosis, putting patients
at risk of liver failure and/or hepatocellular carcinoma (HCC)
[2–4]. Several studies have shown that both the risk for fibrosis
progression and the risk of developing HCC are increased
among patients with HCV GT3 [5, 6].
Therapy for chronic HCV was originally based on interferon,
and resulted in different response rates by genotype [7].Genotypes
2 (GT2) and 3 are relatively interferon sensitive and required
shorter duration of therapy with lower doses of ribavirin
(RBV) to achieve high rates of sustained virologic response
(SVR). Even in the interferon era, data suggested that GT3
was more difficult to cure than GT2, particularly in patients
with established cirrhosis [8]. The discovery of direct-acting
antivirals (DAAs) has revolutionized treatment of chronic
HCV infection. Sofosbuvir (SOF) is a well-tolerated nucleo-
tide polymerase inhibitor with activity against all HCV ge-
notypes. However, despite initially promising results, large
clinical trials reported lower rates of SVR in patients with
GT3 infection receiving SOF-based therapy than with
other HCV genotypes [9].
The FUSION, FISSION, and POSITRON trials showed that
the combination of SOF and RBV was more effective and
much better tolerated than pegylated interferon (peg-IFN)/
RBV in patients with GT2 and GT3 HCV [10, 11]. However,
a breakdown of the results by genotype and cirrhosis status
revealed that patients with GT3, particularly those with cirrho-
sis, had high rates of relapse. With extension of therapy to
24 weeks, the SVR rates rose to 93% in treatment-naive patients;
however, in patients who had failed prior peg-IFN/RBV, the
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SVR rates were 85% without cirrhosis, but only 60% in those
with cirrhosis [12].
Studies then evaluated adding peg-IFN to SOF/RBV for 12
weeks and showed that SVR rates increased to 85%, even in
treatment-experienced patients with cirrhosis [13, 14]. Based
on these results, guidelines recommend either a 12-week course
of SOF/peg-IFN/RBV or a 24-week course of SOF/RBV for pa-
tients with GT3 infection [15, 16].Daclatasvir (DCV), a relative-
ly pan-genotypic NS5A inhibitor, has also been combined with
SOF, and the combination has been recommended as an alter-
native therapy for GT3 infection [15, 16].
The efficacy and safety of these regimens are based on treat-
ments administered to patients who fulfilled the eligibility criteria
for clinical trials. Whether these results apply in daily clinical
practice is unknown. This study reports the safety and effective-
ness of 2 SOF-based regimens for the treatment of chronic GT3
HCV in an international, prospective observational study.
METHODS
Study Population and Design
Hepatitis C Virus Therapeutic Registry and Research Network
(HCV-TARGET) is an international, prospective observational
study enrolling patients from academic (n = 44) and communi-
ty (n = 17) centers in the United States, Canada, Germany, and
Israel who receive antiviral treatment for chronic HCV infec-
tion. Sequentially enrolled patients with no history of liver
transplant or prior DAA treatment, ≥18 years old with GT3
HCV who received treatment with SOF and RBV, with or with-
out peg-IFN, were included. The treatment regimen was chosen
by the treating physician. Redacted medical records were col-
lected by a central team of trained coders and reviewed, and
baseline and on-treatment demographic, clinical, and virologic
data were entered into a common, standardized database. Data
were managed using REDCap electronic data capture tools
hosted at the University of North Carolina at Chapel Hill and
reviewed for completeness and accuracy by study monitors. Ex-
treme or unlikely values were verified or resolved with addition-
al queries.
The protocol was conducted in accordance with the Declara-
tion of Helsinki and Good Clinical Practice guidelines. The pro-
tocol was approved by each local institutional review board
(IRB). All patients provided written informed consent or an in-
formed consent waiver was granted by the IRB overseeing the
site.
Definitions
The following clinical definitions were applied to the study
population.
Cirrhosis. Cirrhosis was defined by an algorithm imple-
mented for HCV-TARGET analyses [17]. The primary indicator
of cirrhosis was a liver biopsy withMetavir score F4. Patients with
a liver biopsy reported as Metavir score F3 with at least 1 second-
ary indicator were also defined as having cirrhosis. Secondary
indicators included serum fibrosis scores above thresholds for cir-
rhosis (FibroSure/FibroTest, FibroSpect, Hepascore); transient
elastography (Fibroscan) ≥12.5 kPa; or signs of portal hyperten-
sion (esophageal/gastric varices, portal gastropathy, or platelet
count <140 000/µL). In the absence of a biopsy, patients with
≥2 secondary indicators were defined as having cirrhosis [18].
Decompensated cirrhosis was defined as documented pres-
ence of current or past ascites, hepatic encephalopathy, sponta-
neous bacterial peritonitis, hepatic hydrothorax or variceal
hemorrhage, or use of medications specifically prescribed for
one of these indications.
Adverse Event. An adverse event (AE) was defined as any
reported AE regardless of the need for dose reduction or discon-
tinuation of HCV therapy.
Serious Adverse Event. A serious adverse event (SAE) was
defined as an AE that either required hospitalization or met cri-
teria for expedited reporting per US Food and Drug Adminis-
tration form MEDWATCH 3500.
Anemia. Anemia was reported as an AE, or documented
RBV dose reduction, treatment with erythropoietin, or blood
transfusion.
Statistical Analyses
Demographics, baseline laboratory values, and frequencies of
AEs were collected and analyzed by treatment regimen for the
evaluable population (N = 197), which comprised patients who
ended treatment with a known virologic outcome or were con-
firmed to be lost to posttreatment follow-up (counted as non–
virologic failures). Those lost to follow-up during treatment or
who withdrew consent were excluded.
The per-protocol population (n = 174) comprised patients
who completed treatment or ended treatment early due to viro-
logic failure only, and have a known virologic outcome.
The unadjusted rates of SVR were calculated for the evaluable
and per-protocol populations, and multivariable analyses of fac-
tors associated with response and results in subgroups of inter-
est are reported for the per-protocol population, including
treatment history, presence of cirrhosis, and features of cirrho-
sis. Confidence intervals (CIs) of unadjusted rates were calculat-
ed using exact binomial methods.
The association between baseline covariates and SVR was es-
timated by logistic regression adjusted for age and sex for the
per-protocol population. Covariates significant after adjustment
for age and sex without significant collinearity were combined
into multivariable models. Predictor variables were selected a
priori based on consensus of clinical expertise and included
well-established covariates associated with SVR: treatment reg-
imen, age, sex, race, albumin level (<3.2 g/dL, ≥3.2 g/dL), plate-
let count (<105 cells/µL, ≥105 cells/µL), creatinine clearance,
total bilirubin (mg/dL), hemoglobin (g/dL), cirrhosis status,
and history of prior antiviral treatment as well as Model for
End-Stage Liver Disease score and history of decompensating
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event in patients with cirrhosis. Results are presented as an odds
ratio (OR) with 95% CIs. Analyses were performed using SAS
version 9.4 software (SAS Institute, Cary, North Carolina).
RESULTS
Patient Disposition
Between December 2013 and January 2015, 210 patients with
GT3 HCV infection with no history of liver transplant or
prior DAA therapy started treatment with SOF/RBV or SOF/
peg-IFN/RBV. A total of 185 patients completed the prescribed
regimen. Eighteen patients discontinued treatment early due to
AEs [4], lack of efficacy [4], noncompliance [3], or other reasons
[3] (eg, loss of insurance or planned surgery). Twelve patients
were excluded due to loss to follow-up during treatment [4],
withdrawal of consent [1], or ongoing posttreatment follow-
up at the time of reporting [5].
The majority of patients (178/197 [90%]) were treated with
SOF/RBV, with 87% receiving 24±2 weeks of therapy, while 19
(10%) patients received 12 (n = 12), 16 (n = 1), or 24 (n = 5)
weeks of SOF/peg-IFN/RBV, including 1 patient who discontin-
ued treatment at week 4. In total, 112 (57%) were male, 81% were
white, and the mean age was 56 years (range, 27–77 years). Just
under half (49%) were treatment experienced and 3 patients
(1.5%) were coinfected with human immunodeficiency virus
(HIV). Of 107 (54%) patients with cirrhosis, 49 (46%) had a
history of prior hepatic decompensation. Of cirrhotic patients
with complete MELD data (70%), the median baseline MELD
score was 10 (range, 6–24). MELD score was <10 in 49%
(n = 37), 10–15 in 44% (n = 33), and >15 in 7% (n = 5) of patients
with cirrhosis (Table 1; Supplementary Table 1).
Treatment Response
SVR12 was achieved by 107 of 178 (60.1%) patients treated with
SOF/RBV. The reasons for virologic failure included relapse in
50 (28%) patients, viral breakthrough in 6 patients (3.4%), and
lack of efficacy in 1 patient (<0.5%). Fourteen patients (8%) were
lost to posttreatment follow-up and were counted as failing treat-
ment. Of those who received SOF/peg-IFN/RBV, 16 of 19 (84%)
achieved SVR12; 1 was a nonresponder and 2 relapsed (Table 2).
In the per-protocol population, the SVR12 rate was similar in
patients without cirrhosis who received SOF/RBV, whether treat-
ment naive (41/46 [89%]) or experienced (22/25 [88%]). In pa-
tients with cirrhosis treated with SOF/RBV, the SVR12 rate was
58% (19 of 33) in treatment-naive patients and fell to 42% (22
of 52) in those who had failed prior therapy (Table 2). In contrast,
of 8 treatment-experienced patients with cirrhosis who received
SOF/peg-IFN/RBV, 7 (88%) achieved SVR12 (Table 2). Overall,
treatment with SOF/RBV was associated with a lower rate of
SVR than treatment with SOF/peg-IFN/RBV (OR, 0.25; 95%
CI, .06–1.13), but the difference did not reach statistical signifi-
cance given the few patients treated with triple therapy. After
Table 1. Baseline Demographic and Clinical Characteristics of Patients With Genotype 3 Hepatitis C Virus Who Completed Therapy With Sofosbuvir and
Ribavirin With or Without Peginterferon
Characteristic SOF/Peg-IFN/RBV (n = 19) SOF/RBV (n = 178) Total (N = 197)
Age, y
18–39 3 (15.8) 19 (10.7) 22 (11.2)
40–64 15 (78.9) 140 (78.7) 155 (78.7)
≥65 1 (5.3) 19 (10.7) 20 (10.2)
Median (range) 56.0 (33–67) 56.0 (27–77) 56.0 (27–77)
Male sex 13 (68.4) 99 (55.6) 112 (56.9)
Race
White 14 (73.7) 146 (82.0) 160 (81.2)
Black 0 (0.0) 4 (2.2) 4 (2.0)
Other/missing 5 (26.3) 28 (15.7) 33 (16.8)
Hispanic ethnicity 2 (10.5) 15 (8.4) 17 (8.6)
Prior HCV treatment
Naive 7 (36.8) 94 (52.8) 101 (51.3)
Experienced 12 (63.2) 84 (47.2) 96 (48.7)
Cirrhosis 11 (57.9) 96 (53.9) 107 (54.3)
History of hepatic decompensation 3 (15.8) 46 (25.8) 49 (24.9)
Baseline MELD score ≥10 2 (25.0) 36 (53.7) 38 (50.7)
HCV RNA, log10 IU/mL, mean (range) 6.3 (4–7) 5.9 (0–8) 5.9 (0–8)
Total bilirubin, mg/dL, median (range) 0.9 (0.2–2.8) 0.7 (0.1–6.6) 0.8 (0.1–6.6)
Albumin, g/dL, median (range) 4.0 (2.4–5.0) 3.9 (2.3–5.0) 3.9 (2.3–5.0)
ALT, mean IU/L, median (range) 74.0 (28.0–375.0) 73.0 (12.0–362.0) 73.0 (12.0–375.0)
Platelet count, ×103 cells/µL, median (range) 132 (59.0–302.0) 134 (22.0–418.0) 133 (22.0–418.0)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; peg-IFN, pegylated interferon; RBV, ribavirin; SOF sofosbuvir.
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controlling for the presence of cirrhosis, neither treatment history
nor treatment duration was associated with SVR.
After controlling for age and sex, the absence of cirrhosis (OR,
6.4; 95% CI, 2.78–14.74), albumin levels of ≥3.2 g/dL (OR, 12.48;
95% CI, 3.86–40.33), and platelet count >105 cells/µL (OR, 7.44;
95% CI, 3.51–15.78) were associated with greater odds of achiev-
ing SVR12, whereas male sex (OR, 0.44; 95% CI, .22–.86) and in-
creasing baseline bilirubin levels (OR, 0.37; 95% CI, .22–.63) were
negative predictors of response (Figure 1).
Among patients with cirrhosis, after controlling for age and sex,
patients with baseline albumin ≥3.2 g/dL (OR, 7.13; 95% CI,
2.09–24.32) and those with platelet count >105 cells/µL (OR,
5.27; 95% CI, 1.84–15.08) were more likely to achieve SVR. In-
creasing baseline total bilirubin (OR, 0.43; 95% CI, .23–.79), base-
line MELD score (OR, 0.75; 95% CI, .61–.92), and history of
decompensating events (OR, 0.29; 95% CI, .12–.70) were each as-
sociated with a decreased likelihood of SVR (Figure 2). The SVR
rate in patients treated with SOF/RBVwith compensated cirrhosis
was 64.8% (35/54) compared with 36% (4/11) in those with a his-
tory of decompensated disease (P = .08). Baseline HCV RNAwas
not predictive of SVR.Week 4 HCV RNAvalues were available in
153 patients (81%) and although patients with undetectable HCV
RNA by week 4 were more likely to achieve SVR, this did not
reach statistical significance (P = .09).
Table 2. Virologic Response in Patients With Genotype 3 Hepatitis C Virus Who Completed Therapy With Sofosbuvir and Ribavirin With or Without
Peginterferon
Treatment Regimen SOF/Peg-IFN/RBV (n = 19) SOF/RBV (n = 178) Total (N = 197)
Overall SVR12 (EP) 16/19 (84.2%) 107/178 (60.1%) 123/197 (62.4%)
PP SVR12 16/18 (88.9%) 104/156 (66.7%) 120/174 (69.0%)
Noncirrhotic Cirrhotic Noncirrhotic Cirrhotic
Overall SVR12 (EP) 87.5% (7/8) 81.8% (9/11) 78.1% (64/82) 44.8% (43/96)
PP SVR12 87.5% (7/8) 90% (9/10) 88.7% (63/71) 48.2% (41/85)
TN TE TN TE TN TE TN TE
SVR12 (EP) 100% (4/4) 75% (3/4) 66.7% (2/3) 87.5% (7/8) 75.0% (42/56) 84.6% (22/26) 55.3% (21/38) 37.9% (22/58)
SVR12 (PP) 100% (4/4) 75% (3/4) 100% (2/2) 87.5% (7/8) 89.1% (41/46) 88.0% (22/25) 57.6% (19/33) 42.3% (22/52)
Virologic failure (EP)
Breakthrough . . . . . . . . . . . . 1 1 2 2 6
Relapse . . . 1 . . . 1 7 3 12 28 52
Nonresponse . . . . . . 1 . . . . . . . . . . . . 1 2
Non–virologic failure . . . . . . . . . . . . 6 . . . 3 5 14
Abbreviations: EP, evaluable population; peg-IFN, pegylated interferon; PP, per protocol; RBV, ribavirin; SOF sofosbuvir; SVR12, sustained virologic response at 12 weeks; TE, treatment
experienced; TN, treatment naive.
Figure 1. Baseline predictors of sustained virologic response (SVR) among patients with genotype 3 hepatitis C virus treated with sofosbuvir (SOF) and ribavirin (RBV) with or
without peginterferon with available virologic outcomes. Factors associated with SVR are shown with an estimate of the odds ratios (ORs) with 95% confidence interval
determined by multivariable logistic regression for each variable controlled for either age and sex**, or age or sex*. Abbreviations: CrCl, creatinine clearance; HGB, hemo-
globin; LCL, lower confidence limit; TBIL, total bilirubin; UCL, upper confidence limit.
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Adverse Events
At least 1 AE was reported by 86% (169/197), whether treated
with SOF/RBV or SOF/peg-IFN/RBV (Table 3). The most com-
monly reported AEs were fatigue (40%), headache (21%), and
anemia (20%) (Table 3). Rash was reported in 5 (26%) patients
treated with SOF/peg-IFN/RBV and 23 (13%) of those treated
with SOF/RBV. Depression was documented in 25 (14%) pa-
tients on SOF/RBV compared to none on SOF/peg-IFN/RBV.
In total, 11 patients experienced hepatic decompensation dur-
ing therapy, all of whom had a prior history of decompensation
(Table 4). Hepatic encephalopathy (n = 10) was the most fre-
quently reported decompensating event, followed by ascites
(n = 2) and variceal hemorrhage (n = 2).
Anemia was reported in 37 (21%) patients on SOF/RBV and 3
(16%) patients on SOF/peg-IFN/RBV. The median hemoglobin
decline was 2.1 g/dL in SOF/RBV-treated patients, and 2.7 g/dL
in patients treated with SOF/peg-IFN/RBV. Anemia led to RBV
dose reduction in 33 (18.5%) and discontinuation in 2 (10.5%) pa-
tients. The initial RBV dose ranged from 4.6 mg/kg to 19.2 mg/kg
(mean, 13.1 mg/kg). As shown in the forest plots (Figures 1 and
2), initial RBV dose was not associated with SVR in those with
cirrhosis but was associated with SVR in the overall population,
suggesting the effect was greatest in those without cirrhosis. The
correlation between RBV dose and SVR is shown in Figure 3. RBV
dose reduction was not associated with SVR (Figure 1 and 2).
Addition of erythropoietin was needed by 7 patients (4%) and a
blood transfusion by 4 (2%) individuals, all in patients treated with
SOF/RBV. A total of 18 SAEs were reported in 13 patients (all
treated with SOF/RBV), of which 8 SAEs in 7 patients were likely
related to HCV therapy per the treating physician.
Table 3. Adverse Events and Management of Anemia
Event
SOF/Peg-IFN/





Any adverse event 15 (79.0) 154 (86.5) 169 (85.8)
Fatigue 8 (42.1) 70 (39.3) 78 (39.6)
Headache 4 (21.1) 38 (21.4) 42 (21.3)
Anemia 3 (15.8) 37 (20.8) 40 (20.3)
Insomnia 2 (10.5) 35 (19.7) 37 (18.8)
Nausea 1 (5.3) 33 (18.5) 34 (17.3)
Rash 5 (26.3) 23 (12.9) 28 (14.2)
Dyspnea 2 (10.5) 25 (14.0) 27 (13.7)
Influenza-like illness 5 (26.3) 21 (11.8) 26 (13.2)
Depression 0 (0.0) 25 (14.0) 25 (12.7)
Dizziness 2 (10.5) 21 (11.8) 23 (11.7)
Irritability 3 (15.8) 19 (10.7) 22 (11.2)
Pruritus 2 (10.5) 20 (11.2) 22 (11.2)
Decreased appetite 3 (15.8) 15 (8.4) 18 (9.1)
Abdominal pain 3 (15.8) 13 (7.3) 16 (8.1)
Asthenia 2 (10.5) 13 (7.3) 15 (7.6)
Diarrhea 2 (10.5) 11 (6.2) 13 (6.6)
Muscle spasms 2 (10.5) 11 (6.2) 13 (6.6)
Cough 2 (10.5) 11 (6.2) 13 (6.6)
Serious adverse events
(18 events)a
0 (0.0) 13 (7.3) 13 (6.6)
Anemia management
RBV dose reduction 2 (10.5) 33 (18.5) 35 (17.8)
Erythropoietin use 0 (0.0) 7 (3.9) 7 (3.6)
Blood transfusion 0 (0.0) 4 (2.2) 4 (2.0)
RBV discontinuation 0 (0.0) 1 (0.6) 1 (0.5)
Data are presented as No. (%) of patients.
Abbreviations: peg-IFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir.
a Anemia, colitis, gastrointestinal hemorrhage, esophageal varices hemorrhage, chest pain,
hepatocellular carcinoma (2), hepatic encephalopathy (4), dizziness (2), depression, psychotic
disorder, renal failure acute (2), epistaxis.
Figure 2. Baseline predictors of sustained virologic response (SVR) among patients with genotype 3 hepatitis C virus and cirrhosis treated with sofosbuvir (SOF) and
ribavirin (RBV) with or without peginterferon with available virologic outcomes. Factors associated with SVR among patients with cirrhosis are shown with an estimate of
the odds ratios (ORs) with 95% confidence interval determined by multivariable logistic regression for each variable controlled for either age and sex**, or age or sex*.
Abbreviations: CrCl, creatinine clearance; HGB, hemoglobin; LCL, lower confidence limit; MELD, Model for End-Stage Liver Disease; TBIL, total bilirubin; UCL, upper con-
fidence limit.
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DISCUSSION
This large observational study evaluated the effectiveness and
safety of 2 SOF-based therapies in patients with GT3 HCV in-
fection. Although treatment was generally safe and fairly well
tolerated, the SVR12 results were suboptimal (69%), particularly
in patients with cirrhosis treated with SOF/RBV alone, high-
lighting the need for improved therapies for this population.
As reported in clinical trials, the main determinant of out-
come in GT3 infection was the presence of cirrhosis [10–12].
Less than half (48%) of those with cirrhosis treated with SOF/
RBV achieved SVR12. Notably, cirrhosis was a negative predic-
tor of response even in patients who were previously untreated.
Although the VALENCE trial reported a 92% SVR rate in treat-
ment-naive patients with cirrhosis, only 13 such patients were
included in the trial [12]. In this real-world study, only 19 of
the 33 (58%) treatment-naive patients with cirrhosis achieved
SVR12. Whether this reflects differences between clinical trials
and clinical practice, or inclusion of patients with more ad-
vanced disease, or highlights the uncertainty of drawing conclu-
sions from the small numbers included in the trial is difficult to
determine.
How cirrhosis affects response to therapy is not clear but is
likely multifactorial [20].Data from patients with genotype 1 in-
fection suggest that even in a cirrhotic liver, SOF is effectively
taken up by hepatocytes and phosphorylated to the active com-
pound [20]. Shunting due to portal hypertension may affect
local drug concentrations and cirrhosis has important effects
on innate and adaptive immune function, which are likely still
important for viral clearance even with potent DAA therapy
[20]. Younossi and colleagues recently reported that patients
with GT3 infection had lower levels of lipids and, specifically,
lower levels of metabolites from late in the cholesterol biosyn-
thesis pathway [21]. Although the specific mechanisms remain
unclear, these findings support the hypothesis that the unique
effects of GT3 HCV on lipid metabolism may affect responses
to antiviral therapy, an effect that appears to be more pronounced
in the presence of cirrhosis. Unfortunately, cirrhosis is important
even when SOF is combined with other approved DAAs for GT3
infection. Only 63% of patients with cirrhosis achieved SVR when
SOF was combined with DCV for 12 weeks [22]. In the small
ALLY 3+ study, patients with GT3 HCV and cirrhosis who re-
ceived SOF/DCV plus RBV for 12 or 16 weeks achieved SVR
rates of 83%–89%; however, the small sample size makes it difficult
to draw strong conclusions or to distinguish the preferred duration
[23].Additional data from the French compassionate use program
showed that 24 weeks of SOF/DCV with or without RBV led to
Table 4. Details on 14 Decompensation Events in 11 Patients During Antiviral Therapy
Patient ID Decompensation Event Regimen Releated to Treatment Timing of Event, wk Past History of Decompensation Treatment Outcome
1 Hepatic encephalopathy SOF/RBV N 8.3 Y SVR
2 Hepatic encephalopathy SOF/RBV Y 16.1 Y Relapse
3 Variceal hemorrhage SOF/RBV N 11.7 Y Relapse
4 Hepatic encephalopathy SOF/RBV Y 4.9 Y Relapse
4 Hepatic encephalopathy SOF/RBV Y 24.4 Y Relapse
5 Variceal hemorrhage SOF/RBV Y 0.4 Y SVR
6 Hepatic encephalopathy SOF/RBV Y 0.1 Y Relapse
7 Hepatic encephalopathy SOF/RBV Y 19.4 Y SVR
7 Hepatic encephalopathy SOF/RBV Y 16.6 Y SVR
8 Hepatic encephalopathy SOF/RBV Y 0.1 Y LTFU
8 Ascites SOF/RBV Y 9 Y LTFU
9 Hepatic encephalopathy SOF/RBV N 4.3 Y BT
10 Hepatic encephalopathy SOF/RBV Y 4.9 Y BT
11 Ascites SOF/RBV Y 13.3 Y SVR
Abbreviations: BT, breakthrough (on treatment); LTFU, lost to posttreatment follow-up; SOF/RBV, sofosbuvir/ribavirin; SVR, sustained virologic response.
Figure 3. Correlation of probability of sustained virologic response at 12 weeks
(SVR12) and initial ribavirin (RBV) dose (by body weight [BW]; mg/kg). The impact of
the initial dose of RBV is shown by estimating the probability of SVR according to
initial RBV dose using observed SVR (circle) and observed virologic failure (diamond),
The shaded area shows the 95% confidence interval (CI) for the estimated
correlation.
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SVR rates >80% despite inclusion of some patients with decom-
pensated disease [24].SOF/RBV plus LDV has also been evaluated
in GT3 HCV. With the very limited activity of LDV against GT3
in vitro, it was perhaps surprising to see SVR rates as high as 73%
in patients with cirrhosis [25]. These results clearly leave room for
improvement for patients with GT3 infection and cirrhosis.
The disappointing outcomes with SOF/RBV therapy led to
evaluation of the reintroduction of peg-IFN. Similar to the ini-
tial small studies evaluating this approach, the SOF/peg-IFN/
RBV regimen proved quite effective in this cohort, most notably
in the 8 patients with cirrhosis who had failed prior therapy, 7 of
whom achieved SVR. A randomized controlled trial comparing
SOF/RBV for 16 or 24 weeks to SOF/peg-IFN/RBV for 12 weeks
in patients with GT3 HCV [14] showed that the inclusion of
peg-IFN increased response rates in all patient subgroups but
most notably in those with cirrhosis, whether treatment naive
or experienced. Peg-IFN was well tolerated, with only 1 patient
discontinuing treatment prematurely. Similarly, in this real-
world experience, peg-IFN was well tolerated, with similar rates
of AEs and higher rates of SVR reported compared with SOF/
RBV alone. However, despite these encouraging results, SOF/
peg-IFN/RBV was prescribed to only 19 of the 197 (9.6%) pa-
tients with GT3 who have started therapy in HCV-TARGET to
date. Clearly there is a great reluctance by both clinicians and pa-
tients to accept interferon-based therapies. Fortunately, recent
studies have shown that SOF combined with velpatasvir, a pan-
genotypic NS5A inhibitor, is highly effective for GT3 HCV infec-
tion, leading to SVR12 rates of 90% even in patients with cirrho-
sis, without the need for RBV [26]. Other promising DAA
combinations hold promise for GT3 HCV as well [27]. With
this in mind, although SOF/peg-IFN/RBV may be considered
for patients, particularly those with cirrhosis, waiting for approval
of new therapies may be prudent, as it is unclear if an unsuccessful
course of SOF/RBV or SOF/DCV will affect responses and/or ac-
cess to future therapies.
Among patients with cirrhosis, low baseline albumin and low
platelet count were associated with much lower odds of achieving
SVR12. Only 20% of patients with albumin levels <3.2 g/dL
achieved SVR, whereas 39% with baseline platelet count <105
cells/µL achieved SVR12 with SOF/RBV. Of the 18 patients
with albumin <3.2 g/dL and platelets <105 cells/µL, only 4
(22%) achieved SVR, suggesting that for such individuals, waiting
for availability of new multi-DAA regimens would be advisable.
This study has some important limitations. The lack of ran-
domization limits the ability to directly compare treatment
groups, which is further compounded by the small number of
patients who received SOF/peg-IFN/RBV therapy. However, the
results clearly demonstrate the limitations of SOF/RBV in pa-
tients with GT3 HCV infection and cirrhosis. In addition, by
including a broader population of patients, many of whom
may not have qualified for clinical trials, the safety and effective-
ness profile provide very useful data for clinicians and patients.
CONCLUSIONS
This large observational, real-world study demonstrated that
GT3 remains a clinical challenge. SOF/RBV for 24 weeks result-
ed in low SVR rates in patients with cirrhosis, particularly those
with low baseline albumin and platelet levels. Although high ef-
ficacy and acceptable tolerability were seen in patients treated
with SOF/peg-IFN/RBV, the extremely low uptake of this regi-
men highlights the poor acceptance of peg-IFN among patients
and clinicians. Therapies in development will hopefully im-
prove outcomes for this difficult-to-cure population.
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